Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MLYCD | O95822 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696786 | 0.84 | MLYCD (0.69) | SMN1; SMN2MLYCDNPC1RAB9AKMT2A | |
| SCHEMBL1016035 | 0.82 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL3936872 | 0.81 | MAPT (0.60) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL1019065 | 0.80 | MLYCD (0.65) | ALDH1A1SMN1; SMN2MLYCDNPC1RAB9A | |
| SCHEMBL8789867 | 0.79 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL12047925 | 0.79 | ALDH1A1 (0.89) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL6578873 | 0.77 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNACYP2C9CYP2C19 | |
| SCHEMBL1706262 | 0.76 | MAPT (0.53) | ALDH1A1SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL3864570 | 0.76 | PTGS2 (0.59) | ALDH1A1SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL8029965 | 0.76 | KMT2A (0.60) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | ALDH1A1 3049/4885SMN1; SMN2 4561/4885LMNA 4335/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | ALDH1A1 3049/4885SMN1; SMN2 4561/4885LMNA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.